•
Dec 31, 2020
Y-mAbs Q4 2020 Earnings Report
Y-mAbs reported financial results for 2020, highlighting the approval of DANYELZA and the sale of a Priority Review Voucher.
Key Takeaways
Y-mAbs reported its 2020 financial results, which included a net loss, revenues from licensing agreements, and increased operating expenses. The company had $114.6 million in cash and cash equivalents as of December 31, 2020.
Y-mAbs reported a net loss of $119.3 million for the year ended December 31, 2020.
Net revenues of $20.8 million were reported for the year ended December 31, 2020, related to licensing agreements.
Research and development expenses increased by $30.2 million to $93.7 million for the year ended December 31, 2020.
The Company had approximately $114.6 million in cash and cash equivalents as of December 31, 2020.